Barry Wohl

Barry Wohl has diverse operating and strategic planning experience in both the medical device and biopharma sectors. He is currently Chief Business Officer at Apnimed, a venture-backed, clinical-stage company developing novel pharmaceuticals for Obstructive Sleep Apnea. Previously, he was Senior Director of Alliances at Macrolide Pharmaceuticals. Prior to that role, he co-founded Symbal Therapeutics and led the company to sublicense its lead development candidate to a pharmaceutical partner. He has also worked with global biotech firms of all sizes and development stages as a strategy consultant with IMS Consulting Group (now IQVIA) and concurrently in a sell-side transaction advisory role with IMS Health Capital. He started his career with Medtronic, where he worked as a product design engineer and later as a global clinical trial lead. Barry holds degrees in biomedical and mechanical engineering, and an MBA from Harvard Business School.